Advertisement

Topics

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

2010-07-15 17:00:00 | BioPortfolio

Summary

The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Focal Segmental Glomerulosclerosis

Intervention

FG-3019

Location

New Hyde Park
New York
United States
11040

Status

Terminated

Source

FibroGen

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [265 Associated Clinical Trials listed on BioPortfolio]

Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis

The purpose of this study is to analyze the safety, renal function, metabolic disorders and quality of life data in patients with focal segmental glomerulosclerosis treated with endovascul...

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe an...

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS). The high...

Rituximab Treatment of Focal Segmental Glomerulosclerosis

The purpose of this study is to determine whether the approved drug, rituximab, is effective in the treatment of focal segmental glomerulosclerosis (FSGS)

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis

PubMed Articles [994 Associated PubMed Articles listed on BioPortfolio]

Diagnosis and primary care management of focal segmental glomerulosclerosis in children.

Focal segmental glomerulosclerosis (FSGS) is a pattern of kidney damage that can occur in individuals at any age, including children. Pediatric patients with FSGS require medication monitoring, growth...

Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury demonstrated by renal biopsy that can arise from a diverse range of causes and mechanisms. It has an estimated incidence of ...

Diagnosis and primary care management of focal segmental glomerulosclerosis in children.

ACTH Gel in Resistant Focal Segmental Glomerulosclerosis after Kidney Transplantation.

Treatment of focal segmental glomerular sclerosis (FSGS) after kidney transplantation is challenging with unpredictable outcomes. The objective was to investigate the use of adrenocorticotropic hormon...

Generation of two isogenic iPS cell lines (IRFMNi002-A and IRFMNi002-B) from a patient affected by Focal Segmental Glomerulosclerosis carrying a heterozygous c.565G>A mutation in PAX2 gene.

Focal Segmental Glomerulosclerosis (FSGS) is the typical renal histologic lesion in familial steroid-resistant nephrotic syndrome, for which there is currently no treatment. Dysfunction of the glomeru...

Medical and Biotech [MESH] Definitions

A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.

An ApoL protein highly expressed by the liver. It has anti-trypanosomal activity through its ability to permeabilize TRYPANOSOMA membranes. Mutations in the APOL1 gene are associated with type 4 FOCAL SEGMENTAL GLOMERULOSCLEROSIS .

A non-selective, calcium permeant TRPC cation channel that contains four ANKYRIN REPEATS and is activated by DIACYLGLYCEROL independently of PROTEIN KINASE C. It is expressed in placenta, lung, spleen, ovary and the small intestine, as well as by PODOCYTES in the kidney glomerulus. Mutations in the TRPC6 gene are associated with FOCAL SEGMENTAL GLOMERULOSCLEROSIS type 2.

Renal syndrome in human immunodeficiency virus-infected patients characterized by nephrotic syndrome, severe proteinuria, focal and segmental glomerulosclerosis with distinctive tubular and interstitial changes, enlarged kidneys, and peculiar tubuloreticular structures. The syndrome is distinct from heroin-associated nephropathy as well as other forms of kidney disease seen in HIV-infected patients.

INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.

More From BioPortfolio on "Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial